Brief: Algernon Pharmaceuticals Announces NP-120, Its Lead Compound In Idiopathic Pulmonary Fibrosis (IPF) Research Program, Is A Drug Called Ifenprodil

Grey Matters Health

29/07/2019 13:41

July 29 (Reuters) - Algernon Pharmaceuticals Inc  AGN.CD :
    * ALGERNON PHARMACEUTICALS - ANNOUNCES NP-120, ITS LEAD
COMPOUND
IN IDIOPATHIC PULMONARY FIBROSIS (IPF) RESEARCH PROGRAM, IS A
DRUG CALLED IFENPRODIL
    * ALGERNON - SINCE NP-120 (IFENPRODIL) IS ALREADY APPROVED
WITH
ESTABLISHED SAFETY HISTORY, CO INTENDS TO MOVE DRUG DIRECTLY
INTO PHASE II HUMAN TRIAL

Source text for Eikon:  ID:nGNXdKlTh 
Further company coverage:  AGN.CD 

 ((Reuters.Briefs@thomsonreuters.com;))